Similar articles

• HSV-2 suppression reduces HIV and HSV shedding.

  Collins S. Collins S. GMHC Treat Issues. 2005 Dec;19(12):11. GMHC Treat Issues. 2005. PMID: 16909510 Clinical Trial. No abstract available.
• A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.

  Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DH. Yi TJ, et al. Clin Infect Dis. 2013 Nov;57(9):1331-8. doi: 10.1093/cid/cit539. Epub 2013 Aug 14. Clin Infect Dis. 2013. PMID: 23946220 Clinical Trial.
• Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.

  Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, Miller G, Corey L. Gupta R, et al. J Infect Dis. 2004 Oct 15;190(8):1374-81. doi: 10.1086/424519. Epub 2004 Sep 20. J Infect Dis. 2004. PMID: 15378428 Clinical Trial.
• Recent developments in the management of herpes simplex virus infection in HIV-infected persons.

  Bartlett JG. Bartlett JG. Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S237-9. doi: 10.1086/422360. Clin Infect Dis. 2004. PMID: 15494894 Review. No abstract available.
• HSV shedding.

  Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ. Sacks SL, et al. Antiviral Res. 2004 Aug;63 Suppl 1:S19-26. doi: 10.1016/j.antiviral.2004.06.004. Antiviral Res. 2004. PMID: 15450382 Review.